Cardiotoxicity of Novel Targeted Hematological Therapies

Valentina Giudice, Carmine Vecchione, Carmine Selleri

Research output: Contribution to journalReview articlepeer-review

Abstract

Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways important not only in cancer cells but also in myocytes. For example, Bruton's tyrosine kinase (BTK) inhibitors interfere with class I phosphoinositide 3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various channel forming proteins; thus, off-target effects of BTK inhibitors are associated with increased frequency of arrhythmias, such as atrial fibrillation, compared to standard chemotherapy. In this review, we summarize current knowledge of cardiotoxic effects of targeted therapies used in hematology.

Original languageEnglish
JournalLife
Volume10
Issue number12
DOIs
Publication statusPublished - Dec 11 2020

Fingerprint

Dive into the research topics of 'Cardiotoxicity of Novel Targeted Hematological Therapies'. Together they form a unique fingerprint.

Cite this